{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:45:33Z","timestamp":1790430333131,"version":"4.1.0"},"reference-count":184,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001702","name":"AO Trauma","doi-asserted-by":"publisher","award":["AR2022_01"],"award-info":[{"award-number":["AR2022_01"]}],"id":[{"id":"10.13039\/501100001702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001702","name":"AO Trauma","doi-asserted-by":"publisher","award":["P50 AR072000"],"award-info":[{"award-number":["P50 AR072000"]}],"id":[{"id":"10.13039\/501100001702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001702","name":"AO Trauma","doi-asserted-by":"publisher","award":["T32 GM007356"],"award-info":[{"award-number":["T32 GM007356"]}],"id":[{"id":"10.13039\/501100001702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001702","name":"AO Trauma","doi-asserted-by":"publisher","award":["T32 GM152318"],"award-info":[{"award-number":["T32 GM152318"]}],"id":[{"id":"10.13039\/501100001702","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Health","award":["AR2022_01"],"award-info":[{"award-number":["AR2022_01"]}]},{"name":"National Institute of Health","award":["P50 AR072000"],"award-info":[{"award-number":["P50 AR072000"]}]},{"name":"National Institute of Health","award":["T32 GM007356"],"award-info":[{"award-number":["T32 GM007356"]}]},{"name":"National Institute of Health","award":["T32 GM152318"],"award-info":[{"award-number":["T32 GM152318"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Sitafloxacin is a 4th generation fluoroquinolone antibiotic with broad activity against a wide range of Gram-negative and Gram-positive bacteria. It is approved in Japan and used to treat pneumonia and urinary tract infections (UTIs) as well as other upper and lower respiratory infections, genitourinary infections, oral infections and otitis media. Compared to other fluoroquinolones, sitafloxacin displays a low minimal inhibitory concentration (MIC) for many bacterial species but also activity against anaerobes, intracellular bacteria, and persisters. Furthermore, it has also shown strong activity against biofilms of P. aeruginosa and S. aureus in vitro, which was recently validated in vivo with murine models of S. aureus implant-associated bone infection. Although limited in scale at present, the published literature supports the further evaluation of sitafloxacin in implant-related infections and other biofilm-related infections. The aim of this review is to summarize the chemical-positioning-based mechanisms, activity, resistance profile, and future clinical potential of sitafloxacin.<\/jats:p>","DOI":"10.3390\/ph17111537","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T05:36:45Z","timestamp":1731908205000},"page":"1537","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antibacterial Mechanisms and Clinical Impact of Sitafloxacin"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2470-6641","authenticated-orcid":false,"given":"Elian M. A.","family":"Kuhn","sequence":"first","affiliation":[{"name":"AO Research Institute Davos, 7270 Davos, Switzerland"},{"name":"Infection Biology, Biozentrum, University of Basel, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8084-3187","authenticated-orcid":false,"given":"Levy A.","family":"Sominsky","sequence":"additional","affiliation":[{"name":"Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY 14642, USA"},{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA"},{"name":"Medical Scientist Training Program, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-9515","authenticated-orcid":false,"given":"Marco","family":"Chitt\u00f2","sequence":"additional","affiliation":[{"name":"AO Research Institute Davos, 7270 Davos, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4854-9698","authenticated-orcid":false,"given":"Edward M.","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2307-0397","authenticated-orcid":false,"given":"T. Fintan","family":"Moriarty","sequence":"additional","affiliation":[{"name":"AO Research Institute Davos, 7270 Davos, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,16]]},"reference":[{"key":"ref_1","unstructured":"Daiichi Sankyo Co., Ltd. (2009). Fine Granules 10%: Prescribing Information, Japan. Gracevit\u00ae Tablets 50 mg, Fine Granules 10%: Prescribing Information, Daiichi Sankyo Co., Ltd."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/11207380-000000000-00000","article-title":"Sitafloxacin: In bacterial infections","volume":"71","author":"Keating","year":"2011","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s10156-012-0392-9","article-title":"Clinical and microbiological outcomes in treatment of men with non-gonococcal urethritis with a 100-mg twice-daily dose regimen of sitafloxacin","volume":"18","author":"Ito","year":"2012","journal-title":"J. Infect. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3201\/eid2608.191806","article-title":"Doxycycline and Sitafloxacin Combination Therapy for Treating Highly Resistant Mycoplasma genitalium","volume":"26","author":"Durukan","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/jm01240a021","article-title":"1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents","volume":"5","author":"Lesher","year":"1962","journal-title":"J. Med. Pharm. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1128\/AAC.10.1.20","article-title":"Bioevaluation of the antibacterial flumequine for urinary tract use","volume":"10","author":"Rohlfing","year":"1976","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1128\/AAC.17.2.103","article-title":"In vitro antibacterial activity of AM-715, a new nalidixic acid analog","volume":"17","author":"Ito","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.7326\/0003-4819-108-2-238","article-title":"Norfloxacin: A new targeted fluoroquinolone antimicrobial agent","volume":"108","author":"Wolfson","year":"1988","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1128\/CMR.2.4.378","article-title":"Fluoroquinolone antimicrobial Agents","volume":"2","author":"Wolfson","year":"1989","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1469-0691.2005.01131.x","article-title":"Quinolones in 2005: An update","volume":"11","author":"Michot","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jac\/dkg208","article-title":"The quinolones: Decades of development and use","volume":"51","author":"Emmerson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jac\/13.1.87","article-title":"The pharmacokinetics and tissue penetration of norfloxacin","volume":"13","author":"Adhami","year":"1984","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/AAC.27.1.76","article-title":"Activities of new quinoline derivatives against genital pathogens","volume":"27","author":"Aznar","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1007\/BF01650504","article-title":"Worldwide clinical data on efficacy and safety of ciprofloxacin","volume":"16","author":"Schacht","year":"1988","journal-title":"Infection"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1086\/515132","article-title":"Safety of long-term therapy with ciprofloxacin: Data analysis of controlled clinical trials and review","volume":"28","author":"Segev","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.jac.a020889","article-title":"Quinolone generations: Natural history or natural selection?","volume":"46","author":"Ball","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1086\/428051","article-title":"The quinolones: Past, present, and future","volume":"41","author":"Andriole","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/cr030101q","article-title":"Bacterial topoisomerase inhibitors: Quinolone and pyridone antibacterial Agents","volume":"105","author":"Mitscher","year":"2005","journal-title":"Chem. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0149-2918(98)80104-5","article-title":"Levofloxacin: A therapeutic review","volume":"20","author":"Wimer","year":"1998","journal-title":"Clin. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/j.1875-9114.1998.tb03925.x","article-title":"Levofloxacin, a second-generation fluoroquinolone","volume":"18","author":"North","year":"1998","journal-title":"Pharmacotherapy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00003495-199447040-00008","article-title":"Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ajhp\/58.5.379","article-title":"Moxifloxacin: Clinical efficacy and safety","volume":"58","author":"Culley","year":"2001","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00003495-199957030-00007","article-title":"Moxifloxacin","volume":"57","author":"Balfour","year":"1999","journal-title":"Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1345\/aph.1E003","article-title":"Gemifloxacin: A new fluoroquinolone approved for treatment of respiratory infections","volume":"38","author":"Yoo","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1586\/14789072.2.6.831","article-title":"Gemifloxacin: A new, potent fluoroquinolone for the therapy of lower respiratory tract infections","volume":"2","author":"File","year":"2004","journal-title":"Expert Rev. Ant. Infect. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0149-2918(00)89007-4","article-title":"Sparfloxacin: A review","volume":"22","author":"Schentag","year":"2000","journal-title":"Clin. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Bush, N.G., Diez-Santos, I., Abbott, L.R., and Maxwell, A. (2020). Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance. Molecules, 25.","DOI":"10.3390\/molecules25235662"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/jac\/33.4.685","article-title":"Structure-activity and structure-side-effect relationships for the quinolone antibacterials","volume":"33","author":"Domagala","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1085\/jgp.52.3.495","article-title":"Permeability of lipid bilayer membranes to organic solutes","volume":"52","author":"Bean","year":"1968","journal-title":"J. Gen. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/AAC.37.7.1393","article-title":"Penetration of lipophilic agents with multiple protonation sites into bacterial cells: Tetracyclines and fluoroquinolones as examples","volume":"37","author":"Nikaido","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/clinids\/10.Supplement_1.S132","article-title":"Drug interactions with quinolones","volume":"10","author":"Lode","year":"1988","journal-title":"Rev. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12300","DOI":"10.1074\/jbc.M113.529164","article-title":"Fluoroquinolone-gyrase-DNA complexes: Two modes of drug binding","volume":"289","author":"Mustaev","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1021\/bi500682e","article-title":"Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1093\/nar\/gkt124","article-title":"Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: Mechanistic basis of quinolone resistance","volume":"41","author":"Aldred","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Carter, H.E., Wildman, B., Schwanz, H.A., Kerns, R.J., and Aldred, K.J. (2023). Role of the Water-Metal Ion Bridge in Quinolone Interactions with Escherichia coli Gyrase. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032879"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/260643a0","article-title":"Nalidixic acid and bacterial chromosome replication","volume":"260","author":"Crumplin","year":"1976","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1073\/pnas.73.11.3872","article-title":"DNA gyrase: An enzyme that introduces superhelical turns into DNA","volume":"73","author":"Gellert","year":"1976","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1073\/pnas.74.11.4772","article-title":"Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity","volume":"74","author":"Gellert","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/ecosalplus.esp-0010-2014","article-title":"DNA Topoisomerases","volume":"6","author":"Bush","year":"2015","journal-title":"EcoSal Plus"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1073\/pnas.74.11.4767","article-title":"Mechanism of action of nalidixic acid: Purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme","volume":"74","author":"Sugino","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/jmbi.1994.1586","article-title":"The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase","volume":"242","author":"Willmott","year":"1994","journal-title":"J. Mol. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1006\/jmbi.1996.0274","article-title":"DNA gyrase and topoisomerase IV on the bacterial chromosome: Quinolone-induced DNA cleavage","volume":"258","author":"Chen","year":"1996","journal-title":"J. Mol. Biol."},{"key":"ref_43","first-page":"377","article-title":"DNA gyrase, topoisomerase IV, and the 4-quinolones","volume":"61","author":"Drlica","year":"1997","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1365-2958.2006.05275.x","article-title":"Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones","volume":"61","author":"Malik","year":"2006","journal-title":"Mol. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"a025320","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1128\/AAC.46.6.1800-1804.2002","article-title":"Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis","volume":"46","author":"Onodera","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/jac\/dkn136","article-title":"Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: Contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae","volume":"62","author":"Okumura","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jac\/44.4.533","article-title":"Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae","volume":"44","author":"Onodera","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2165\/00003495-199958002-00120","article-title":"Inhibition of Pneumococcal Topoisomerases by Sitafloxacin","volume":"58","author":"Morrissey","year":"1999","journal-title":"Drugs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jgar.2022.06.003","article-title":"Antimicrobial activities of sitafloxacin and comparators against the clinical isolates of less common nonfermenting Gram-negative bacteria","volume":"30","author":"Zhou","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_51","first-page":"S6","article-title":"Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections","volume":"95","author":"Tiengrim","year":"2012","journal-title":"J. Med. Assoc. Thai."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jmii.2014.02.002","article-title":"Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complex","volume":"48","author":"Huang","year":"2015","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1128\/AAC.01105-10","article-title":"Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development","volume":"55","author":"Yamamoto","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Choi, Y.I., Lee, S.M., Chung, J.W., Kim, K.O., Kwon, K.A., Kim, Y.J., Kim, J.H., Lee, S.M., Jeong, J.Y., and Park, D.K. (2021). Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Helicobacter Eradication in Korea: An In Vitro Culture-Based Study. Antibiotics, 10.","DOI":"10.3390\/antibiotics10101242"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijantimicag.2005.10.006","article-title":"In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus","volume":"27","author":"Yamamoto","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/apm.12777","article-title":"In vitro activity and time-kill curve analysis of sitafloxacin against a global panel of antimicrobial-resistant and multidrug-resistant Neisseria gonorrhoeae isolates","volume":"126","author":"Foerster","year":"2018","journal-title":"Apmis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jac\/46.1.109","article-title":"In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus","volume":"46","author":"Schmitz","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s10096-021-04278-3","article-title":"Comparative activities of sitafloxacin against recent clinical isolates in hospitals across China","volume":"40","author":"Wu","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.46.3.813-820.2002","article-title":"Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae","volume":"46","author":"Piddock","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1093\/clinids\/23.Supplement_1.S25","article-title":"Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: Review of current information on efficacy and safety","volume":"23","author":"Goldstein","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1128\/AAC.38.10.2504","article-title":"In vitro activity of DU-6859a against anaerobic bacteria","volume":"38","author":"Wexler","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/clinids\/23.Supplement_1.S31","article-title":"Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria","volume":"23","author":"Kato","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrmicro1384","article-title":"Small colony variants: A pathogenic form of bacteria that facilitates persistent and recurrent infections","volume":"4","author":"Proctor","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrmicro1557","article-title":"Persister cells, dormancy and infectious disease","volume":"5","author":"Lewis","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1038\/s41467-018-06527-0","article-title":"Prolonged bacterial lag time results in small colony variants that represent a sub-population of persisters","volume":"9","author":"Vulin","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1128\/CMR.00069-15","article-title":"Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections","volume":"29","author":"Kahl","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4137\/MBI.S25800","article-title":"Phenotypic and Genotypic Characteristics of Small Colony Variants and Their Role in Chronic Infection","volume":"8","author":"Johns","year":"2015","journal-title":"Microbiol. Insights"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/jac\/dkt072","article-title":"Antibiotic activity against small-colony variants of Staphylococcus aureus: Review of in vitro, animal and clinical data","volume":"68","author":"Garcia","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.injury.2006.04.006","article-title":"The small colony variant (SCV) concept\u2014The role of staphylococcal SCVs in persistent infections","volume":"37","author":"Peters","year":"2006","journal-title":"Injury"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/jac\/dkv371","article-title":"Staphylococcus aureus develops increased resistance to antibiotics by forming dynamic small colony variants during chronic osteomyelitis","volume":"71","author":"Tuchscherr","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/mSphere.00422-18","article-title":"A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants","volume":"3","author":"Trombetta","year":"2018","journal-title":"mSphere"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2014920118","DOI":"10.1073\/pnas.2014920118","article-title":"Molecular reprogramming and phenotype switching in Staphylococcus aureus lead to high antibiotic persistence and affect therapy success","volume":"118","author":"Huemer","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/mdr.2019.0425","article-title":"Antibiotic Tolerance in Biofilm and Stationary-Phase Planktonic Cells of Staphylococcus aureus","volume":"27","author":"Kamble","year":"2021","journal-title":"Microb. Drug Resist."},{"key":"ref_74","first-page":"235","article-title":"Staphylococcus aureus persisters tolerant to bactericidal antibiotics","volume":"22","author":"Lechner","year":"2012","journal-title":"J. Mol. Microbiol. Biotechnol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"She, P., Li, S., Liu, Y., Xu, L., Zhou, L., Zeng, X., Li, Y., Liu, S., Li, Z., and Hussain, Z. (2021). Repurposing Sitafloxacin, Prulifloxacin, Tosufloxacin, and Sisomicin as Antimicrobials Against Biofilm and Persister Cells of Pseudomonas aeruginosa. Curr. Microbiol., 79.","DOI":"10.1007\/s00284-021-02729-w"},{"key":"ref_76","first-page":"207","article-title":"Staphylococcal biofilms","volume":"322","author":"Otto","year":"2008","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1128\/microbiolspec.VMBF-0022-2015","article-title":"The Staphylococcal Biofilm: Adhesins, Regulation, and Host Response","volume":"4","author":"Paharik","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Thi, M.T.T., Wibowo, D., and Rehm, B.H.A. (2020). Pseudomonas aeruginosa Biofilms. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228671"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4014\/jmb.1611.11056","article-title":"Pseudomonas aeruginosa Biofilm, a Programmed Bacterial Life for Fitness","volume":"27","author":"Lee","year":"2017","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/08959374970110010701","article-title":"Biofilm susceptibility to antimicrobials","volume":"11","author":"Gilbert","year":"1997","journal-title":"Adv. Dent. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/apm.12673","article-title":"Antibiotic treatment of biofilm infections","volume":"125","author":"Ciofu","year":"2017","journal-title":"Apmis"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ja.2012.7","article-title":"Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: Comparison with levofloxacin and moxifloxacin","volume":"65","author":"Shi","year":"2012","journal-title":"J. Antibiot."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.2042-7158.1998.tb07140.x","article-title":"Uptake of fluoroquinolones in human monocytes isolated from peripheral blood","volume":"50","author":"Dorian","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jac\/dkn232","article-title":"Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes","volume":"62","author":"Nguyen","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/jac\/dkg483","article-title":"Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data","volume":"53","author":"Phillips","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1128\/MMBR.00016-10","article-title":"Origins and evolution of antibiotic resistance","volume":"74","author":"Davies","year":"2010","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"976273","DOI":"10.1155\/2012\/976273","article-title":"Global fluoroquinolone resistance epidemiology and implictions for clinical use","volume":"2012","author":"Dalhoff","year":"2012","journal-title":"Interdiscip. Perspect. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/jac\/dkt212","article-title":"Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: Links to prescribing change?","volume":"68","author":"Livermore","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4137\/PMC.S14459","article-title":"Antibiotics and bacterial resistance in the 21st century","volume":"6","author":"Fair","year":"2014","journal-title":"Perspect. Medicin. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3947\/ic.2014.46.4.226","article-title":"Clinical importance and epidemiology of quinolone resistance","volume":"46","author":"Kim","year":"2014","journal-title":"Infect. Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/infdis\/jiv279","article-title":"The Rise of Fluoroquinolone-Resistant Escherichia coli in the Community: Scarier Than We Thought","volume":"212","author":"Spellberg","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/AAC.43.2.302","article-title":"ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae","volume":"43","author":"Varon","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/AAC.45.12.3544-3547.2001","article-title":"Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition","volume":"45","author":"Takei","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1128\/AAC.46.8.2712-2715.2002","article-title":"Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae","volume":"46","author":"Houssaye","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1128\/AAC.46.2.522-524.2002","article-title":"Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin","volume":"46","author":"Li","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/AAC.41.10.2289","article-title":"Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa","volume":"41","author":"Nakano","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/AAC.40.3.710","article-title":"Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene","volume":"40","author":"Kumagai","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2958.1994.tb00458.x","article-title":"Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones","volume":"13","author":"Ferrero","year":"1994","journal-title":"Mol. Microbiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1128\/AAC.41.11.2362","article-title":"Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus","volume":"41","author":"Tanaka","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_100","first-page":"1017","article-title":"Moxifloxacin and Sitafloxacin Treatment Failure in Mycoplasma genitalium Infection: Association with parC Mutation G248T (S83I) and Concurrent gyrA Mutations","volume":"221","author":"Murray","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/jac\/dkad208","article-title":"Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: A prospective cohort study","volume":"78","author":"Ando","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0732-8893(02)00498-4","article-title":"Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada","volume":"45","author":"Zhanel","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1128\/JB.185.23.6883-6892.2003","article-title":"Quinolone resistance due to reduced target enzyme expression","volume":"185","author":"Ince","year":"2003","journal-title":"J. Bacteriol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nm1347","article-title":"Fluoroquinolone-modifying enzyme: A new adaptation of a common aminoglycoside acetyltransferase","volume":"12","author":"Robicsek","year":"2006","journal-title":"Nat. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jiac.2014.08.021","article-title":"Sitafloxacin: Antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV","volume":"21","author":"Deguchi","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1128\/AAC.01552-08","article-title":"Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations","volume":"53","author":"Murakami","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/AAC.00049-09","article-title":"Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation","volume":"53","author":"Suzuki","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jiac.2020.07.009","article-title":"Sitafloxacin has a potent activity for eradication of extended spectrum \u03b2-lactamase-producing fluoroquinolone-resistant Escherichia coli forming intracellular bacterial communities in uroepithelial cells","volume":"26","author":"Hiyama","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1099\/jmm.0.000493","article-title":"In vitro activity of sitafloxacin against Mycobacterium tuberculosis with gyrA\/B mutations isolated in Japan","volume":"66","author":"Yi","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e21216","DOI":"10.1016\/j.heliyon.2023.e21216","article-title":"Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China","volume":"9","author":"Kong","year":"2023","journal-title":"Heliyon"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/jac\/dki191","article-title":"Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates","volume":"56","author":"Gillespie","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1128\/JB.00807-06","article-title":"Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin","volume":"188","author":"Cirz","year":"2006","journal-title":"J. Bacteriol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1128\/JB.01464-06","article-title":"Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin","volume":"189","author":"Cirz","year":"2007","journal-title":"J. Bacteriol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2958.2007.05642.x","article-title":"Antibiotic-mediated recombination: Ciprofloxacin stimulates SOS-independent recombination of divergent sequences in Escherichia coli","volume":"64","author":"Elez","year":"2007","journal-title":"Mol. Microbiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1128\/AAC.00358-09","article-title":"Effect of subinhibitory concentrations of antibiotics on intrachromosomal homologous recombination in Escherichia coli","volume":"53","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.resmic.2009.03.003","article-title":"Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response","volume":"160","author":"Tattevin","year":"2009","journal-title":"Res. Microbiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/jac\/dkn387","article-title":"Mycobacterium tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacin","volume":"62","author":"Hinds","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Torres-Barcel\u00f3, C., Kojadinovic, M., Moxon, R., and MacLean, R.C. (2015). The SOS response increases bacterial fitness, but not evolvability, under a sublethal dose of antibiotic. Proc. Biol. Sci., 282.","DOI":"10.1098\/rspb.2015.0885"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0732-8893(96)00197-6","article-title":"Bactericidal activity of the fluoroquinolone DU-6859a alone and in combination with other antimicrobial agents against multiresistant enterococci","volume":"26","author":"Korten","year":"1996","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jac\/dkac365","article-title":"Sitafloxacin pharmacokinetics\/pharmacodynamics against multidrug-resistant bacteria in a dynamic urinary tract infection in vitro model","volume":"78","author":"Guo","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Watanabe, J., Ihara, H., Takei, S., Nakamura, A., Fujimoto, Y., Handoh, T., Kurokawa, K., Arai, Y., Shibayama, K., and Sumiyoshi, I. (2023). The synergetic effect of sitafloxacin-arbekacin combination in the Mycobacterium abscessus species. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-29021-0"},{"key":"ref_122","first-page":"8135","article-title":"In vitro activities of sitafloxacin tested alone and in combination with rifampin, colistin, sulbactam, and tigecycline against extensively drug-resistant Acinetobacter baumannii","volume":"8","author":"Dong","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Rodjun, V., Houngsaitong, J., Montakantikul, P., Paiboonvong, T., Khuntayaporn, P., Yanyongchaikit, P., and Sriyant, P. (2020). In Vitro Activities of Colistin and Sitafloxacin Combinations against Multidrug-, Carbapenem-, and Colistin-Resistant Acinetobacter baumannii Using the Broth Microdilution Checkerboard and Time-Kill Methods. Antibiotics, 9.","DOI":"10.3390\/antibiotics9080516"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jac\/dkf218","article-title":"In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans","volume":"50","author":"Dhople","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1179\/joc.2003.15.1.47","article-title":"Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice","volume":"15","author":"Dhople","year":"2003","journal-title":"J. Chemother."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Sirijatuphat, R., Thawornkaew, S., Ruangkriengsin, D., and Thamlikitkul, V. (2022). Colistin Monotherapy versus Colistin plus Sitafloxacin for Therapy of Carbapenem-Resistant Acinetobacter baumannii Infections: A Preliminary Study. Antibiotics, 11.","DOI":"10.3390\/antibiotics11121707"},{"key":"ref_127","first-page":"3485","article-title":"Sulbactam enhances the in vitro activity of sitafloxacin against extensively-drug resistant Acinetobacter baumannii","volume":"16","author":"Xu","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Adjei-Sowah, E., Peng, Y., Weeks, J., Jonason, J.H., de Mesy Bentley, K.L., Masters, E., Morita, Y., Muthukrishnan, G., Cherian, P., and Hu, X.E. (2021). Development of Bisphosphonate-Conjugated Antibiotics to Overcome Pharmacodynamic Limitations of Local Therapy: Initial Results with Carbamate Linked Sitafloxacin and Tedizolid. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060732"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Ren, Y., Xue, T., Rainbolt, J., Bentley, K.L.M., Galloway, C.A., Liu, Y., Cherian, P., Neighbors, J., Hofstee, M.I., and Ebetino, F.H. (2022). Efficacy of Bisphosphonate-Conjugated Sitafloxacin in a Murine Model of S. aureus Osteomyelitis: Evidence of \u201cTarget & Release\u201d Kinetics and Killing of Bacteria Within Canaliculi. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.910970"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41413-023-00287-4","article-title":"Evidence of bisphosphonate-conjugated sitafloxacin eradication of established methicillin-resistant S. aureus infection with osseointegration in murine models of implant-associated osteomyelitis","volume":"11","author":"Ren","year":"2023","journal-title":"Bone Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3947\/ic.2018.50.1.67","article-title":"Clinical Practice Guidelines for the Antibiotic Treatment of Community-Acquired Urinary Tract Infections","volume":"50","author":"Kang","year":"2018","journal-title":"Infect. Chemother."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2165\/00003495-200464120-00007","article-title":"Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections","volume":"64","author":"Carson","year":"2004","journal-title":"Drugs"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jinf.2011.05.015","article-title":"Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region","volume":"63","author":"Hsueh","year":"2011","journal-title":"J. Infect."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/07853890.2020.1861322","article-title":"A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection","volume":"53","author":"Li","year":"2021","journal-title":"Ann. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1155\/2005\/385768","article-title":"Complicated urinary tract infection in adults","volume":"16","author":"Nicolle","year":"2005","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/IDR.S178183","article-title":"Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: A randomized controlled trial","volume":"12","author":"Lojanapiwat","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10156-011-0329-8","article-title":"Antimicrobial efficacies of several antibiotics against uterine cervicitis caused by Mycoplasma genitalium","volume":"18","author":"Terada","year":"2012","journal-title":"J. Infect. Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s10156-013-0620-y","article-title":"Clinical efficacy of sitafloxacin 100 mg twice daily for 7 days for patients with non-gonococcal urethritis","volume":"19","author":"Takahashi","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_139","first-page":"763","article-title":"Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections","volume":"75","author":"Iwata","year":"2021","journal-title":"Acta Med. Okayama"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0029-1202941","article-title":"Global and local epidemiology of community-acquired pneumonia: The experience of the CAPNETZ Network","volume":"30","author":"Welte","year":"2009","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jama.2016.0115","article-title":"Antibiotic Therapy for Adults Hospitalized with Community-Acquired Pneumonia: A Systematic Review","volume":"315","author":"Lee","year":"2016","journal-title":"JAMA"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Zhou, M., Wang, L., Wang, Z., Kudinha, T., Wang, Y., Xu, Y., and Liu, Z. (2022). Molecular Characterization of Penicillin-Binding Protein2x, 2b and 1a of Streptococcus pneumoniae Causing Invasive Pneumococcal Diseases in China: A Multicenter Study. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.838790"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/03007995.2021.1885362","article-title":"A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia","volume":"37","author":"Li","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0924-8579(00)00344-7","article-title":"An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem\/cilastatin in the intravenous treatment of hospitalised patients with pneumonia","volume":"17","author":"Feldman","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc703","article-title":"Helicobacter pylori and gastrointestinal tract adenocarcinomas","volume":"2","author":"Peek","year":"2002","journal-title":"Nat. Rev. Cancer."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2005.03.083","article-title":"Helicobacter pylori and MALT lymphoma","volume":"128","author":"Farinha","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199104113241507","article-title":"Helicobacter pylori and peptic ulcer disease","volume":"324","author":"Peterson","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e12597","DOI":"10.1111\/hel.12597","article-title":"Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition","volume":"24","author":"Kato","year":"2019","journal-title":"Helicobacter"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s00535-012-0731-8","article-title":"Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan","volume":"48","author":"Murakami","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Nishizawa, T., Munkjargal, M., Ebinuma, H., Toyoshima, O., and Suzuki, H. (2021). Sitafloxacin for Third-Line Helicobacter pylori Eradication: A Systematic Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122722"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2011.12.002","article-title":"Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan","volume":"39","author":"Hirata","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijid.2016.08.019","article-title":"Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen","volume":"51","author":"Hirata","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/jgh.14456","article-title":"Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori","volume":"34","author":"Sue","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1128\/AAC.05941-11","article-title":"Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies","volume":"56","author":"Matsuzaki","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Saito, Y., Konno, K., Sato, M., Nakano, M., Kato, Y., Saito, H., and Serizawa, H. (2019). Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori. Cancers, 11.","DOI":"10.3390\/cancers11010116"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/jgh.12442","article-title":"Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan","volume":"29","author":"Furuta","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/hel.12286","article-title":"Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation","volume":"21","author":"Mori","year":"2016","journal-title":"Helicobacter"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1159\/000501610","article-title":"10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy","volume":"101","author":"Mori","year":"2020","journal-title":"Digestion"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/apt.13280","article-title":"High Helicobacter pylori cure rate with sitafloxacin-based triple therapy","volume":"42","author":"Sugimoto","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Sugimoto, M., Hira, D., Murata, M., Kawai, T., and Terada, T. (2020). Effect of Antibiotic Susceptibility and CYP3A4\/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy. Antibiotics, 9.","DOI":"10.3390\/antibiotics9100645"},{"key":"ref_163","first-page":"38","article-title":"Clinical problems of H. pylori eradication therapy after application expansion of the health insurance","volume":"44","author":"Tokunaga","year":"2014","journal-title":"J. Germfree Life Gnotobiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cgh.2011.02.019","article-title":"Clinical and histopathologic features of fluoroquinolone-induced liver injury","volume":"9","author":"Orman","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_165","unstructured":"US Foot & Drug (2024, August 08). FDA Updates Warnings for Fluoroquinolone Antibiotics on Risks of Mental Health and Low Blood Sugar Adverse Reactions, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-updates-warnings-fluoroquinolone-antibiotics-risks-mental-health-and-low-blood-sugar-adverse."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/WNL.0000000000000846","article-title":"Oral fluoroquinolone use and risk of peripheral neuropathy: A pharmacoepidemiologic study","volume":"83","author":"Etminan","year":"2014","journal-title":"Neurology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/mol.59.1.122","article-title":"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG","volume":"59","author":"Kang","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/375078","article-title":"Fluoroquinolone-associated tendinopathy: A critical review of the literature","volume":"36","author":"Khaliq","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1001\/archinte.163.15.1801","article-title":"Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids","volume":"163","author":"Sturkenboom","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/600294","article-title":"Severe dysglycemia with the fluoroquinolones: A class effect?","volume":"49","author":"Aspinall","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00002018-200932050-00001","article-title":"Safety profile of the respiratory fluoroquinolone moxifloxacin: Comparison with other fluoroquinolones and other antibacterial classes","volume":"32","author":"Tulkens","year":"2009","journal-title":"Drug Saf."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/AAC.48.3.799-803.2004","article-title":"New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones with various substituents at position 1","volume":"48","author":"Hayashi","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1365-2133.2003.05582.x","article-title":"A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity","volume":"149","author":"Dawe","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jiac.2019.04.019","article-title":"The efficacy and safety of sitafloxacin and garenoxacin for the treatment of pneumonia in elderly patients: A randomized, multicenter, open-label trial","volume":"25","author":"Miyazaki","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref_175","first-page":"81","article-title":"Dose-comparative study of sitafloxacin in complicated urinary tract infections","volume":"56","author":"Kawada","year":"2008","journal-title":"Jpn J. Chemother."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Chen, C.K., Cheng, I.L., Chen, Y.H., and Lai, C.C. (2020). Efficacy and Safety of Sitafloxacin in the Treatment of Acute Bacterial Infection: A Meta-analysis of Randomized Controlled Trials. Antibiotics, 9.","DOI":"10.3390\/antibiotics9030106"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/jac\/46.4.633","article-title":"Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus","volume":"46","author":"Shetty","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Grayson, M.L., Cosgrove, S.E., Crowe, S., Hope, W., McCarthy, J.S., Mills, J., Mouton, J.W., and Paterson, D.L. (2017). Kucers\u2019 The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition\u2014Three Volume Set, Taylor and Francis. [7th ed.].","DOI":"10.1201\/9781498747967"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/0049825011","article-title":"Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucasian subjects","volume":"31","author":"Briggs","year":"2001","journal-title":"Xenobiotica"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/infdis\/159.2.281","article-title":"Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models","volume":"159","author":"Leggett","year":"1989","journal-title":"J. Infect. Dis."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.diagmicrobio.2009.05.006","article-title":"Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates","volume":"65","author":"Yokota","year":"2009","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_183","first-page":"63","article-title":"Open study of sitafloxacin in patients with respiratory tract infections: PK\/PD study","volume":"56","author":"Saito","year":"2008","journal-title":"Jpn J. Chemother."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s10156-012-0543-z","article-title":"Clinical dose findings of sitafloxacin treatment: Pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections","volume":"19","author":"Kohno","year":"2013","journal-title":"J. Infect. Chemother."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1537\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:33:29Z","timestamp":1760114009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,16]]},"references-count":184,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ph17111537"],"URL":"https:\/\/doi.org\/10.3390\/ph17111537","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,16]]}}}